Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.62 |
| ▸ | THRA | P10827 | 15/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120011 | 0.89 | THRA (0.47) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5116739 | 0.89 | THRB (0.60) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5106690 | 0.89 | THRA (0.65) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5110308 | 0.89 | THRB (0.54) | THRBTHRAALDH1A1 | |
| SCHEMBL5117351 | 0.88 | THRB (0.58) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5118576 | 0.87 | ALDH1A1 (0.46) | THRBTHRAKMT2AALDH1A1 | |
| SCHEMBL4532725 | 0.86 | THRB (0.74) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4348417 | 0.86 | THRB (0.67) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4348412 | 0.86 | THRA (0.77) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5108065 | 0.86 | THRA (0.61) | THRBTHRAESR1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885ESR1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.